Bader A Altulaihi, Khalid G Alharbi, Talal A Alaboodi, Hamad M Alkanhal, Meshal M Alobaid, Maha A Aldraimly
Background The coronavirus disease 2019 (COVID-19), which is also known as severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is an infection that is caused by the novel coronavirus. COVID-19 has severely affected the public health by causing more than 200 million cases and four million deaths worldwide. There are, presently, no specific antiviral treatments for COVID-19. As immunization is one of the most successful and cost-effective health interventions to prevent this infectious disease, a number of vaccines, around 112, have been developed. In Saudi Arabia, many vaccination campaigns have already started. There are currently four approved COVID-19 vaccines but only three are available for use in Saudi Arabia. Methods This was a cross-sectional study in which a web-based survey was distributed to medical students in their clinical years at the College of Medicine in King Saud bin Abdulaziz University, Riyadh, Saudi Arabia. A total of 209 questionnaires were distributed. The survey assessed the demographic data, perception towards COVID-19 vaccine, barriers and predictors for accepting COVID-19 vaccine. Results Two-hundred and four respondents completed the survey with a response rate of 96.7%. Overall, 118 of the participants were males and 86 were females. Sixty-six percent of our participants had taken the vaccine. Of those, males and females were distributed equally in half. Fifty-three percent of the participants who had taken the vaccine aged 21-23. This age group had a significant effect on acceptance of the vaccine. Most common deterrent to taking COVID-19 vaccine was safety issues despite not having a statistical significance. In terms of motivators, the majority thought that fear of getting COVID-19 infection was the most important motivator to taking COVID-19 vaccine, which was statistically significant as well. Conclusion In the setting of spreading COVID-19 infection, the vaccine is still the solution to halting infection spread. Based on our findings, we see that there was a high acceptance rate (66.2%) of COVID-19 vaccine.
Trop Med Health. 2021 May 13;49(1):37
[PMID:
33985592]
J Public Health (Oxf). 2021 Sep 22;43(3):445-449
[PMID:
33367857]
Epidemiol Infect. 2021 May 20;149:e132
[PMID:
34011421]
Arch Iran Med. 2020 Apr 01;23(4):249-254
[PMID:
32271598]
Vaccines (Basel). 2021 Jan 20;9(2):
[PMID:
33498282]
Vaccines (Basel). 2020 Aug 27;8(3):
[PMID:
32867224]
J Multidiscip Healthc. 2020 Nov 20;13:1657-1663
[PMID:
33262600]
JMIR Public Health Surveill. 2020 Apr 30;6(2):e19160
[PMID:
32320381]
Vaccines (Basel). 2021 Mar 05;9(3):
[PMID:
33807732]
J Med Virol. 2021 Jul;93(7):4280-4291
[PMID:
33644891]
BMC Public Health. 2020 Nov 19;20(1):1742
[PMID:
33213391]
Virology. 2020 Dec;551:1-9
[PMID:
33010669]
Hum Vaccin Immunother. 2020 Dec 1;16(12):2905-2912
[PMID:
33232211]